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here Will Be Blood*
rendan Doyle, MD
ochester, Minnesota
leeding in patients with coronary artery disease has at-
racted increasing interest because it has been found to have
ajor implications. Outcomes following acute coronary
yndromes and percutaneous coronary intervention are
uch worse among those patients who experience major
leeding (1,2). What continues to be unclear is whether
leeding identifies a high-risk group by virtue of the
emorrhage itself, by virtue of comorbid illness, or by some
ther mechanism. Recently, suspicion has focused on po-
entially harmful effects of red blood transfusion.
See page 46
In this issue of JACC: Cardiovascular Interventions,
hishehbor et al. (3) have compared the outcomes of
atients who did or did not require blood transfusion during
ospitalization with ST-segment elevation myocardial in-
arction (STEMI). The patient cohort is derived from the
USTO (Global Use of Strategies to Open Occluded
oronary Arteries) IIb trial that compared hirudin with
eparin in patients with acute coronary syndromes. A total
f 3,575 patients who had presented with ST-segment
levation were eligible for analysis, of whom 307 (8.6%)
equired a blood transfusion. The investigators found that
lood transfusion was associated with increased short- and
ong-term mortality in the setting of STEMI.
Patients who needed a blood transfusion were older and
icker than those who did not require transfusion. The study
esign was nonrandomized. In an attempt to overcome
hese limitations, the investigators used multiple statistical
ethods including use of Cox proportional hazards survival
odels with transfusion as a time-dependent covariate for
hole and propensity-matched groups and sensitivity anal-
ses to assess the magnitude of potential hidden bias. The
nvestigators are to be commended for this probing analysis
f the data, wherein blood transfusion remained a strong
redictor of death in the setting of STEMI even after such
djustment. Although not proof of a cause-and-effect rela-
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.p
From the Division of Cardiovascular Diseases, Mayo Clinic College of Medicine,
ochester, Minnesota.ionship, the findings are in agreement with recent data
ighlighting potentially significant risk associated with
lood transfusion among patients with non–STEMI and
atients undergoing percutaneous or surgical revascularization.
What does this mean? Could blood transfusions really be
illing patients? The hypothesis that transfusion may in
ertain circumstances do more harm than good is neither
ew nor surprising. Growing concern, however, reaches
eyond the familiar hazards of microbial transmission and
cute antigen-antibody reactions, with particular focus on
he potential for transfused blood to impair tissue oxygen-
tion. It is well established that stored red blood cells are
ow in 2,3-diphosphoglyceric acid resulting in high oxygen
ffinity (i.e., the hemoglobin will tend not to release oxygen
o the tissues). However, experimental studies now indicate
hat the physiologic impact of 2,3-diphosphoglyceric acid
epletion may have been overstated and that other structural
nd biochemical changes that occur in blood during storage
ay have greater impact on their function in vivo—and may
xplain the paradox whereby increasing hemoglobin by
ransfusion may raise calculated oxygen delivery but measures
f tissue oxygenation either decrease or do not change (4).
Normally, erythrocytes have a flexible membrane and can
eversibly alter their biconcave, discoid shape, thus allowing
hem to pass through capillaries smaller in diameter (2 to 6
m) than red blood cells (8 m). During storage, there is
significant decrease in the deformability of red blood cells.
ther hemorheologic alterations have also been docu-
ented, such as changes in red blood cell shape, decreased
urface/volume ratio, increased mean hemoglobin concen-
ration and osmotic fragility, increased aggregability and
ntracellular viscosity (5). Together, these factors may pre-
ispose to “plugging” of transfused cells at the microvascular
evel, leading to tissue ischemia. It is reasonable to assume
hat vascular beds already compromised by microvascular
ysfunction or obstruction (such as acutely infarcted myo-
ardium) may be particularly vulnerable in this respect.
Attention has also focused on the transport of nitric
xide (NO) by red blood cells. Nitric oxide produced by
ascular endothelium may be bound by erythrocytes in
rotected form as an S-nitrosothiol. Upon release of oxygen,
-nitrosothiol hemoglobin may dispense NO bioactivity to
icrovascular cells, physiologically coupling hemoglobin
eoxygenation to vasodilation (6). This elegant mechanism
acilitates increases in regional blood flow in zones of
ypoxia and, intriguingly, may enable NO-bioactivity to be
mported from a healthy vascular bed to one that is
ompromised by endothelial dysfunction (as would pertain
n the coronary circulation of patients with STEMI).
ecent data indicate that this biochemical function is
ignificantly disrupted by storage of erythrocytes (7). Other
dverse effects of red blood cell transfusion may include
rothrombotic effects, pro-inflammatory, and immunosup-
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Editorial Comment
55ressive effects of cytokines and other infused bioactive
ubstances that accumulate in stored blood.
The study by Shishehbor et al. (3) has a number of
imitations. No information was available regarding associ-
ted transfusions that may have been administered in
ddition to the packed red cell units (such as fresh frozen
lasma or platelets). Such data would be important to help
etermine the specific role of red blood cell transfusion
ersus the effects of severe hemorrhage and/or associated
oagulopathy. The age of stored units was not included in
he GUSTO IIb database but is another important variable
hat may influence the risk associated with transfusion.
lder units exhibit progressive decline in erythrocyte func-
ion and higher levels of potentially harmful cytokines and
ellular breakdown products. The clinical significance of
hese in vitro findings are uncertain, although recent data
rom patients undergoing cardiac surgery suggest that trans-
usion of older rather than fresh blood may indeed be
ssociated with increased risk of adverse events, including
xcess mortality (8). In this context, data regarding the
rgency of transfusion in the study by Shishehbor et al. (3)
ould also have been of interest as O-negative units used in
n emergency setting tend to be older than cross-matched
nits used in an elective setting, and theoretically may carry
xcess risk as a result.
Shishehbor et al. (3) suggest a randomized trial should be
erformed to define the optimal use of blood transfusion in
atients with STEMI. Designing such a trial would be
ifficult. Many would consider it unethical to withhold
ransfusion from an anemic patient who (despite successful
evascularization) exhibits clear evidence of ongoing cardiac
schemia, although a study of fresh versus older blood in this
etting would certainly appear reasonable. A study of blood
ransfusion versus no blood transfusion for asymptomatic
nemia following STEMI would also be of tremendous
nterest, although perhaps more as a means to confirm the
utative adverse effects of transfusion. It is difficult to
elieve that a beneficial effect of transfusion would be
bserved in anemic patients with STEMI who have already
eceived prompt revascularization and who have no evidence
f ongoing ischemia, although this remains an open ques-
ion. Asymptomatic patients who have received incomplete
evascularization might conceivably benefit in the presence
f silent ischemia, particularly in watershed areas of acute
nfarction. Such factors would need to be considered in the
esign and analysis of any future randomized trial.
It is important to emphasize that concerns about possibledverse effects of transfusion should not lead doctors to aithhold blood when it is clearly indicated. Patients who
how symptoms or signs of ischemia are most likely to
erive a net benefit from transfusion, particularly those who
xhibit evidence of oxygen-supply dependency. For asymp-
omatic patients, it would seem prudent to avoid the use of
rbitrary cutoffs (such as a hemoglobin 8 g/dl) to trigger
ransfusion. With minimal potential gain to offset any
dverse effects, transfusion could in theory be more likely to
ause harm in these circumstances. One exception may be
ransfusion of an asymptomatic patient who has anemia
aused by major bleeding and who remains at high risk for
urther bleeding. Greater reserve of red cell mass might
essen the chance that such a re-bleed would be a fatal event.
or the majority of asymptomatic patients, however, this
mportant study by Shishehbor et al. (3) adds to a growing
iterature that prompts us to think twice before deciding
there will be blood.”
eprint requests and correspondence:Dr. Brendan Doyle, Mayo
linic, 200 First Street SW, Rochester, Minnesota 55902. E-mail:
oyle.brendan@mayo.edu.
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